Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder | Not yet recruiting | Not stated | 2026-10-06 | NCT07860814 | |
| Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Not yet recruiting | Phase 4 | 2026-09-29 | NCT07848191 | |
| Resmetirom in Patients With MASH and HFpEF | Heart Failure With Preserved Ejection Fraction (HFPEF); MASH - Metabolic Dysfunction-Associated Steatohepatitis | Not yet recruiting | Phase 1 | 2026-09-21 | NCT07830758 | |
| Study of Resmetirom in Children and Adolescents With MASH | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 2 | 2026-09-11 | NCT07763015 | |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 2 | 2026-08-26 | NCT07335601 | |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05500222 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndrome | Active, not recruiting | Phase 3 | 2026-05-27 | NCT04951219 | |
| Rezdiffra Pregnancy and Lactation Registry | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | Not stated | 2026-04-21 | NCT07541469 |